1. Home
  2. CZNC vs DMAC Comparison

CZNC vs DMAC Comparison

Compare CZNC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

HOLD

Current Price

$22.49

Market Cap

360.7M

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.42

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CZNC
DMAC
Founded
1864
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.7M
428.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CZNC
DMAC
Price
$22.49
$8.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$22.00
$15.50
AVG Volume (30 Days)
43.4K
232.9K
Earning Date
01-22-2026
11-12-2025
Dividend Yield
5.00%
N/A
EPS Growth
22.09
N/A
EPS
1.75
N/A
Revenue
$109,632,000.00
N/A
Revenue This Year
$5.72
N/A
Revenue Next Year
$7.18
N/A
P/E Ratio
$12.77
N/A
Revenue Growth
7.59
N/A
52 Week Low
$18.02
$3.19
52 Week High
$22.68
$10.42

Technical Indicators

Market Signals
Indicator
CZNC
DMAC
Relative Strength Index (RSI) 71.47 53.33
Support Level $21.07 $7.17
Resistance Level $21.76 $8.62
Average True Range (ATR) 0.53 0.56
MACD 0.19 -0.04
Stochastic Oscillator 87.46 74.40

Price Performance

Historical Comparison
CZNC
DMAC

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: